Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Bezuclastinib + Sunitinib

Peak

Cogent Biosciences · Phase 3 · Recruiting · Enrollment 482

NCT05208047

Catalyst Primary completion. 09.30.2025. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst FDA PDUFA target action date (GIST, with sunitinib). 11.30.2026. Company-stated goal date, not a promise of action.

ArmPopulationDoseEstimandComparatorEfficacy
Bezuclastinib 600 mg + sunitinib 37.5 mgGIST after imatinib (n = 204)600 mg + 37.5 mgITTsunitinib 37.5 mgmedian progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025objective response rate (BICR): 46%, data cutoff 09.30.2025PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update
Sunitinib 37.5 mg continuousGIST after imatinib (n = 209)37.5 mgITTn/rmedian progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025objective response rate (BICR): 26%, data cutoff 09.30.2025